What are the recommended treatment regimens for pemphigus vulgaris, bullous pemphigoid, discoid lupus erythematosus, systemic lupus erythematosus with scalp involvement, lichen planopilaris, frontal fibrosing alopecia, and dermatomyositis affecting the face and scalp?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Autoimmune Blistering and Connective Tissue Diseases Affecting Face and Scalp

Pemphigus Vulgaris

Start with oral corticosteroids (prednisolone 1-2 mg/kg/day) combined immediately with a steroid-sparing immunosuppressant—azathioprine (2-3 mg/kg/day if TPMT normal) or mycophenolate mofetil (2-3 g/day)—to achieve disease control and minimize long-term steroid toxicity 1.

First-Line Treatment Algorithm

  • Initial therapy: Prednisolone 1 mg/kg/day is the standard starting dose for most cases 1
  • Dose escalation: If no response within 5-7 days, increase by 50-100% increments until new lesions stop appearing and existing lesions begin healing 1
  • Treatment failure threshold: Failure to achieve control after 3 weeks of prednisolone 1.5 mg/kg/day warrants escalation 1
  • Steroid-sparing agents (start simultaneously, not sequentially):
    • Azathioprine 2-3 mg/kg/day (check TPMT first) 1
    • Mycophenolate mofetil 2-3 g/day 1
    • These agents take weeks to months for full effect but are critical for allowing steroid taper 1

Tapering Strategy

Once disease control is achieved (no new lesions, healing of existing lesions):

  • Reduce prednisolone by 25-50% every 2 weeks until reaching 10 mg/day 1
  • Then taper more slowly (2.5-5 mg decrements every 2-4 weeks) 1
  • Maintain steroid-sparing agent throughout and beyond steroid discontinuation 1

Second and Third-Line Options

  • Rituximab (rheumatoid arthritis protocol: 2 × 1g infusions, 2 weeks apart) is now approved and should be considered for treatment failure with first-line agents 1, 2
  • Alternative agents for refractory disease: cyclophosphamide, methotrexate, IVIG, immunoadsorption, or plasma exchange 1

Critical Pitfall

Corticosteroid-related mortality accounts for up to 77% of pemphigus deaths 1. The primary goal is rapid introduction of steroid-sparing agents to minimize cumulative steroid exposure, not achieving control with steroids alone.


Bullous Pemphigoid

For generalized disease, initiate superpotent topical corticosteroids (clobetasol propionate 0.05%, 10-40 g/day on whole body except face) as first-line therapy, which is superior to oral corticosteroids for extensive disease 3.

Treatment Algorithm by Disease Extent

Localized/Limited Disease:

  • Superpotent topical corticosteroids applied to lesions only 3
  • Alternative: Oral corticosteroids (prednisone 0.5-0.75 mg/kg/day) 3
  • Second-line: Tetracycline + nicotinamide or dapsone 3

Generalized Disease:

  • Primary treatment: Superpotent topical corticosteroids (10-40 g/day whole body, sparing face) for 1-3 weeks 3
  • Alternative primary: Oral prednisone 0.5-0.75 mg/kg/day 3
  • Adjunctive therapy (add if inadequate response within 1-3 weeks):
    • Azathioprine (2-3 mg/kg/day) 3
    • Mycophenolate mofetil (2-3 g/day) 3
    • Methotrexate 3

Maintenance Protocol

After achieving disease control (4 months consolidation phase):

  • Option 1: Continue maintenance with topical corticosteroids 10 g once weekly for 8 months (total 12 months), then stop 3
  • Option 2: Stop treatment after 4 months (slightly higher relapse risk but improved safety) 3

Steroid-Sparing Alternatives

For patients requiring long-term systemic steroids, IVIG and rituximab are effective steroid-sparing options 4. This is particularly important given the elderly population typically affected by bullous pemphigoid.


Discoid Lupus Erythematosus (DLE)

Initiate hydroxychloroquine 200-400 mg/day (or chloroquine if unavailable) combined with high-potency topical corticosteroids and strict photoprotection; add oral corticosteroids as short-term bridging therapy only if needed 5, 6, 5.

Treatment Hierarchy

First-Line:

  • Hydroxychloroquine (antimalarials are recommended for ALL lupus patients unless contraindicated) 6
  • High-potency topical corticosteroids (clobetasol) to active lesions 7
  • Photoprotection (essential adjunct) 5
  • Oral corticosteroids (prednisone ≤7.5 mg/day for shortest duration) only as bridging therapy 6

Second-Line (for inadequate response to antimalarials):

  • Methotrexate 7.5-25 mg weekly (98% showed significant decline in disease activity by 8 weeks in one cohort) 8, 7
  • Retinoids 7
  • Dapsone 7

Third-Line:

  • Mycophenolate mofetil or mycophenolic acid 7
  • Azathioprine 9

Critical Considerations

  • Prompt treatment is crucial because DLE causes irreversible scarring alopecia 7
  • Antimalarials should be continued long-term even after clinical improvement 6
  • Oral corticosteroids should be prescribed at the lowest dose for the shortest time to avoid cumulative toxicity 6

Systemic Lupus Erythematosus with Scalp Involvement

All SLE patients should receive hydroxychloroquine (unless contraindicated) combined with the lowest effective dose of glucocorticoids for the shortest duration; add immunosuppressants (azathioprine, mycophenolate mofetil, or methotrexate) for steroid-sparing in patients requiring prolonged therapy 5, 6, 5.

Standard of Care

  • Hydroxychloroquine (or chloroquine where HCQ unavailable) 6
  • Glucocorticoids (prednisone ≤7.5 mg/day or equivalent) only when clinically indicated 6
  • Photoprotection for all patients with skin manifestations 5

Escalation for Non-Responders

For patients unable to reduce steroids below acceptable chronic doses:

  • Azathioprine 5
  • Mycophenolate mofetil 5
  • Methotrexate 5

Overarching Principles

The 2018 Latin American guidelines emphasize that the therapeutic goal is to reach and maintain remission or low-disease activity as soon as diagnosis is made 6. Treatment must include cardiovascular risk reduction, osteoporosis prevention, infection prophylaxis, and psychological support 6.

Non-Scarring Alopecia in SLE

Management focuses on controlling systemic disease activity; topical medications can expedite recovery 7. Hair regrowth typically follows disease control.


Lichen Planopilaris (LPP) and Frontal Fibrosing Alopecia (FFA)

Initiate combination therapy with oral hydroxychloroquine (200-400 mg/day) or doxycycline (100 mg twice daily) plus high-potency topical or intralesional corticosteroids to halt inflammatory activity before irreversible follicular destruction occurs 10.

First-Line Treatment

Systemic agents:

  • Hydroxychloroquine 200-400 mg/day
  • Doxycycline 100 mg twice daily
  • Oral corticosteroids (short courses only)

Topical/Intralesional:

  • Intralesional corticosteroids (triamcinolone 5-10 mg/mL) reliably achieve disease stabilization and reduce activity scores 10
  • High-potency topical corticosteroids to active areas

Adjunctive Procedural Therapies

Recent evidence supports several procedural modalities as adjuncts to medical therapy:

  • Platelet-rich plasma (PRP): Most consistently reduced activity scores (LPPAI/FFASS) and improved symptoms; several reports documented increases in terminal hair counts and shaft diameter 10
  • Low-level light therapy (LLLT): Improved patient-reported outcomes and modest measurable gains in hair counts/thickness 10
  • Intralesional corticosteroids: Achieved disease stabilization but yielded inconsistent objective regrowth 10

Hair Transplantation Considerations

Hair transplantation may provide good early cosmetic density in quiescent disease only (no active inflammation for ≥12 months), but progressive graft loss occurs by 3-5 years, making long-term durability a major concern 10. This should be reserved for stable, burned-out disease after medical control is achieved.

Treatment Goal

The primary objective is disease stabilization and symptom control rather than hair regrowth, as scarring is irreversible 10. Early aggressive treatment is essential to prevent progression.


Dermatomyositis (Face and Scalp)

Initiate oral corticosteroids (prednisolone 0.5-1 mg/kg/day) combined with a steroid-sparing immunosuppressant (azathioprine or methotrexate preferred) for cutaneous disease; IVIG has the strongest evidence for cutaneous benefit and should be considered early 9, 11.

Treatment Algorithm

First-Line:

  • Oral corticosteroids (prednisolone 0.5-1 mg/kg/day) 9
  • Steroid-sparing agent (start simultaneously):
    • Azathioprine 2-3 mg/kg/day (if TPMT normal) 9
    • Methotrexate 15-25 mg weekly 8

Second-Line (Strongest Cutaneous Evidence):

  • IVIG: Strongest CDASI-based evidence for cutaneous dermatomyositis 11
  • Consider early in disease course, particularly for refractory cutaneous manifestations

Emerging Therapies:

  • Anti-interferon-β therapy: Shows cutaneous benefit 11
  • TYK2/JAK1 inhibitor (brepocitinib): Positive phase 3 trial data for cutaneous outcomes 11

Dermatomyositis-Specific Considerations

Azathioprine is licensed for dermatomyositis and appears effective as a second-line agent in moderate-to-severe, refractory disease 9. However, IVIG has the most consistent validated cutaneous outcome data using CDASI scores 11.

Photoprotection

Essential adjunct therapy for all patients with photosensitive cutaneous manifestations 5.


Key Monitoring and Safety Considerations

Pre-Treatment Screening

For azathioprine:

  • TPMT testing mandatory (0.3% of population has two low-activity alleles and will develop potentially fatal pancytopenia at standard doses) 9

For systemic immunosuppression:

  • CBC, liver/kidney function, hepatitis B/C, HIV serology 3
  • Tuberculosis screening if appropriate 3
  • Pregnancy test in women of childbearing age 3

Corticosteroid Complications

SLE and pemphigus patients are at increased risk for infections, atherosclerosis, hypertension, diabetes, and osteoporosis 5. Minimize corticosteroid dose and duration aggressively:

  • Calcium/vitamin D supplementation 5
  • Bisphosphonates if long-term therapy planned 5
  • Osteodensitometry before initiating long-term steroids 3

Pregnancy Considerations

Safe in pregnancy: Prednisolone, azathioprine, hydroxychloroquine, low-dose aspirin 5

Must avoid: Mycophenolate mofetil, cyclophosphamide, methotrexate 5

References

Research

[Pemphigus: current and future treatment strategies].

Dermatologie (Heidelberg, Germany), 2022

Research

Recent Insight on the Management of Lupus Erythematosus Alopecia.

Clinical, cosmetic and investigational dermatology, 2021

Related Questions

Can Systemic Lupus Erythematosus (SLE) rash involve the forehead and chin?
Which of the following are features of systemic lupus erythematosus: pleuritis, non‑scarring alopecia, Raynaud's phenomenon, erosive joint lesions, or photosensitivity with disease flares after sun exposure?
What are the histopathological features of lichen planopilaris?
What is the differential diagnosis for a skin disease with pathological features including epidermal irregular acanthosis, focal spongiosis, lymphocytic (lymphocyte) exocytosis, interface changes, dermal edema, superficial perivascular lymphocytic infiltrate, and pigment incontinence?
What are the recommended azathioprine dosing, monitoring, and safety guidelines for treating adult pemphigus vulgaris?
In a 52-year-old woman who recently completed oral antibiotics for pyelonephritis and now presents with recurrent urinary symptoms, what medications and diagnostic tests are indicated?
What should be asked during discharge planning for a patient on the hospital floor?
How should an adult with uncomplicated dermatitis properly moisturize the skin using emollients?
In a 30‑year‑old tall Black man with G6PD deficiency, obesity, type 2 diabetes treated with tirzepatide (GLP‑1 agonist) and rapid‑acting insulin, who has progressive proximal muscle weakness, CK elevations (≈371–527 U/L), a persistently positive ANA (1:80 speckled) with markedly elevated anti‑RNP antibodies and negative anti‑SM, anti‑dsDNA, anti‑Jo‑1 and other ENA antibodies, normal ESR/CRP, normal liver enzymes and renal function, what is the most likely diagnosis (inflammatory myositis versus necrotizing autoimmune myopathy), what EMG findings are expected, and what is the prognosis regarding the need for muscle biopsy and corticosteroid therapy?
What is the recommended low‑dose quetiapine regimen for insomnia or anxiety, including starting dose, titration schedule, maximum dose, formulation, contraindications, monitoring, and alternative options?
How should a patient with a recent cranial surgery for an arteriovenous malformation (AVM) be managed for attention‑deficit/hyperactivity disorder (ADHD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.